Digitisation | June 16, 2022
CytoSMART introduces ML algorithm for organoid analysis
The innovative software module is designed to meet growing scientific demand from researchers and drug developers
The innovative software module is designed to meet growing scientific demand from researchers and drug developers
This new formulation represents a significant improvement over protease inhibitor-containing paediatric ARV formulations that have been used in South Africa for decades.
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
Redbiotec has a right to royalties on Eurocine Vaccines´ net sales of an approved HSV-2 vaccine, should such sales arise.
The new program includes upstream and downstream process development and large-scale GMP production.
Group 4 Medulloblastoma is a rare disease that mostly affects pediatric patients, in which aberrant SRC signaling was identified as a hallmark of the disease
The IDCF programme is being implemented from 13th June to 27th June, 2022 in the states/UTs and the goal is to attain zero child deaths due to childhood diarrhoea
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Amarex Clinical Research guides its client to phase II of FDA trials
Subscribe To Our Newsletter & Stay Updated
